US FDA Asks For Public Input On Software It Can't Regulate
FDA is writing a report on key safety impacts from health software products that fall outside of its regulatory purview under the 21st Century Cures Act. To help the effort, the agency is asking industry, patient groups and other stakeholders to chime in by June 28.
You may also be interested in...
Based on a provision in the 21st Century Cures Act, US FDA has released a report that shows that certain types of medical software not regulated by the agency is overwhelmingly beneficial to the public with few risks. The report seems to allay industry fears that FDA may use it to ask for more oversight authority of such products.
A controversial 2016 proposed rule that would have required manufacturers of many class II and class III home-use devices to electronically submit device labeling information to US FDA will not be finalized, the agency affirmed in the Oct. 17 HHS Unified Agenda document. The agency also signaled plans to imminently finalize a broad device classification rule, and other updates.
In a Medtech Insight exclusive podcast interview, US FDA's Bakul Patel talks about what the agency wants to learn from a newly released "working model" intended to set the initial foundations for the digital health pre-certification program. The first version of the program will start before year's end and he's hoping for industry feedback to prepare for it.